Welcome to our dedicated page for Glucotrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on Glucotrack stock.
GlucoTrack, Inc. (NASDAQ: GCTK) generates news primarily around its progress in implantable continuous blood glucose monitoring technology for people with diabetes and the financing activities that support this development. As a medical device and medical technology company, GlucoTrack regularly issues updates on clinical studies, advisory appointments, scientific presentations, and capital formation transactions.
Visitors to this GCTK news page can review press releases on clinical milestones, including GlucoTrack’s first-in-human study of its long-term implantable Continuous Blood Glucose Monitor (CBGM) and the initiation of a long-term, multicenter feasibility study outside the United States. The company also reports on its plans and interactions related to Investigational Device Exemption (IDE) submissions to the U.S. Food and Drug Administration, as described in its own forward-looking statements.
In addition to clinical updates, GlucoTrack publishes news about its clinical advisory team and patient engagement efforts, such as the appointment of specialists in cardiology, neuromodulation, and pain management, and the formation of a Patient Advisory Board. The company’s participation in diabetes-focused conferences and research initiatives, where it presents data on its blood-based, implantable CBGM system and epidural glucose monitoring work, is another frequent topic.
GlucoTrack’s news flow also covers financing and capital structure developments, including equity purchase agreements, private placements, and warrant repurchases described in its press releases and SEC filings. For investors and observers following GCTK, this page offers a consolidated view of GlucoTrack’s publicly disclosed corporate, clinical, and financial announcements related to its investigational CBGM platform and broader diabetes technology strategy.
GlucoTrack, Inc. (Nasdaq: GCTK) announced the launch of a new R&D program aimed at developing a long-term implantable glucose monitor targeting the Type 1 diabetes market. Following the acquisition of related intellectual property, the company aims to create a more accurate and convenient glucose management solution. GlucoTrack also reported positive lab testing results for its non-invasive GlucoTrack 2.0 prototype, with first-in-human trials expected to begin soon. CEO Paul Goode expressed excitement about expanding their product pipeline to benefit people with diabetes.
GlucoTrack, Inc. (Nasdaq: GCTK) provided an update on its GlucoTrack 2.0 development, revealing successful lab testing of its clinical prototype. The company achieved better-than-expected accuracy and performance in bench tests and obtained Ethics Committee approvals for its first in-human clinical study at Rabin Medical Center, Israel, slated for Q3. The forthcoming U.S. study will follow, leading towards FDA clearance. The new design aims for improved user-friendliness and lower costs. CEO Paul Goode expressed optimism about the progress made.
GlucoTrack, Inc. (Nasdaq: GCTK), previously known as Integrity Applications, Inc. (Nasdaq: IGAP), has officially changed its corporate name and ticker symbol as of March 14, 2022. This transition reflects the company's focus on non-invasive glucose monitoring technologies for Type 2 diabetes and prediabetes. The name and symbol changes do not affect stockholder rights or outstanding shares. Shareholders holding physical certificates will receive instructions for exchanging them. GlucoTrack’s device aims to provide a pain-free alternative to traditional glucose monitoring methods.